| The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study. | |
| | |
MedLine Citation:
|
PMID: 11277347 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Elderly patients with acute myelomonocytic leukaemia (AMMoL) frequently have a poor quality of life after induction of remission using high-intensity treatment; we seek a more appropriate regimen for such patients. An 86-year-old man was hospitalized with a diagnosis of AMMoL (FAB classification M4), of abnormal karyotype, and complications of diabetes mellitus and complete right bundle branch block. He was treated with CAG therapy (cytarabine 10 mg/m2 subcutaneously every 12 h for 14 consecutive days; aclarubicin hydrochloride 10 mg/m2 per day, bolus intravenously for 4 consecutive days; granulocyte colony-stimulating factor 100 microg/day, subcutaneous injection for 14 consecutive days) every 3 months. White blood cell counts were at their lowest (around 600 - 800/microl) 12 days after the end of therapy, but returned to about 2000 - 2300/microl 30 days after stopping therapy. No symptoms of drug-related toxicity, except slight nausea, were found. Complete remission with a good quality of life was induced and lasted over 2 years suggesting that CAG therapy might prove effective in elderly patients with AMMoL. |
| | |
Authors:
|
T Tsuda; Y Okamoto; R Sakaguchi; N Katayama; K Ota |
Related Documents
:
|
2715557 - Hypochondriasis in the elderly depressed. 22136557 - Consistency of gina criteria and childhood asthma control test on the determination of ... 6859297 - Major depression in the elderly: dsm-iii criteria and the dexamethasone suppression tes... 12540347 - Quality of spirometric performance in older people. 22939877 - Quality of life among alcohol-dependent patients: how satisfactory are the available in... 16951107 - Depression in orthopaedic trauma patients. prevalence and severity. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: The Journal of international medical research Volume: 29 ISSN: 0300-0605 ISO Abbreviation: J. Int. Med. Res. Publication Date: 2001 Jan-Feb |
Date Detail:
|
Created Date: 2001-03-29 Completed Date: 2001-07-19 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0346411 Medline TA: J Int Med Res Country: England |
Other Details:
|
Languages: eng Pagination: 41-7 Citation Subset: IM |
Affiliation:
|
Department of Blood Transfusion Medicine and Clinical Hematology, Wakayama Medical College, Wakayama City, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aclarubicin
/
therapeutic use* Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Cytarabine / therapeutic use* Granulocyte Colony-Stimulating Factor / therapeutic use* Humans Leukemia, Myelomonocytic, Acute / drug therapy*, pathology Male |
| Chemical | |
Reg. No./Substance:
|
0/CAG protocol; 143011-72-7/Granulocyte Colony-Stimulating Factor; 147-94-4/Cytarabine; 57576-44-0/Aclarubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiac beriberi among illegal mainland Chinese immigrants.
Next Document: C-reactive protein values and erythrocyte sedimentation rates after total hip and total knee arthrop...